Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Medicine’s Generic Tacrolimus Wins NMPA Approval for Transplant Rejection Prevention

Fineline Cube Jul 4, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received market approval...

Company

Medtronic Kanghui and Changzhou High-Tech Zone Partner on Science Park

Fineline Cube Jul 4, 2022

Medtronic Kanghui and Changzhou National High-Tech Industrial Development Zone have agreed to collaborate on the...

Policy / Regulatory

NHC Releases Technical Guidelines for Drug Clinical Evaluation

Fineline Cube Jul 4, 2022

The National Health Commission (NHC) has released the “Technical Guidelines for Comprehensive Clinical Evaluation of...

Company Deals

HitGen and Haichang Bio Partner to Develop Anti-Cancer RNAi Drugs

Fineline Cube Jul 4, 2022

China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...

Policy / Regulatory

Hainan Medical Products Administration Issues Guidelines for Imported Drug Management

Fineline Cube Jul 4, 2022

The Hainan Medical Products Administration (HMPA) has released a set of guidelines that took effect...

Company Drug

Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors

Fineline Cube Jul 4, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...

Company Drug

Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide

Fineline Cube Jul 4, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in...

Company Deals

Fosun Pharmaceutical and ReNeuron Renew CTX Cell Therapy Deal for China

Fineline Cube Jul 4, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has negotiated a new...

Company

Eurofins DiscoverX Opens Shanghai Office to Expand Asia-Pacific Operations

Fineline Cube Jul 4, 2022

California-based Eurofins DiscoverX Products LLC, a manufacturer of drug discovery solutions, announced the opening of...

Company Deals

Solasia Pharma Reduces China Operations, Transfers Drug Rights to Lee’s

Fineline Cube Jul 4, 2022

Japan-based Solasia Pharma KK (TYO: 4597) announced that it will reduce its direct operations in...

Policy / Regulatory

NMPA Releases Plans to Support HK and Macau Drug, Device Production in Mainland Cities

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has released two implementation plans aimed at supporting Hong...

Company Drug

Bio-Thera Solutions’ BAT8010 Receives NMPA Approval for Solid Tumor Clinical Trials

Fineline Cube Jul 1, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that it has received approval from the National Medical...

Company Drug

Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC

Fineline Cube Jul 1, 2022

The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...

Company R&D

Burning Rock Biotech Launches PREVENT Study for Early Cancer Detection

Fineline Cube Jul 1, 2022

Chengdu-based medical device firm Burning Rock Biotech Ltd (NASDAQ: BNR) announced the launch of a...

Company Deals

Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing

Fineline Cube Jul 1, 2022

China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...

Policy / Regulatory

NMPA Releases 55th Batch of Reference Drugs for Generic Evaluation

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has released the 55th batch of reference drugs for...

Company Drug

BeiGene’s Tislelizumab Shows Survival Benefit in Esophageal Cancer Study

Fineline Cube Jul 1, 2022

BeiGene (NASDAQ: BGNE) has released the latest results of the global Phase III RATIONALE 306...

Policy / Regulatory

NMPA Releases Work Plans for Temporary Import of Urgently Needed Drugs

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has officially released the “Work Plan for the Temporary...

Company Drug

Huadong Medicine’s Biosimilar Ozempic (Semaglutide) Wins NMPA Clinical Trial Approval

Fineline Cube Jul 1, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...

Drug

Jixing Pharmaceuticals Enrolls First Patient in Etripamil Phase III Study for PSVT

Fineline Cube Jul 1, 2022

China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III...

Posts pagination

1 … 610 611 612 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.